Jeff Walsh Email and Phone Number
Jeff Walsh work email
- Valid
- Valid
Jeff Walsh personal email
- Valid
Jeff Walsh phone numbers
More than 30 years of experience with high growth, public and private life sciences companies including Chief Financial Officer, Chief Operating Officer & Chief Strategy Officer roles with responsibility for strategy, finance, business development, program leadership, commercial development, operations and legal functions.- Joined Third Rock Ventures in 2022 as a Venture Partner with the hope of helping to build some of the next great healthcare breakthrough companies.- Joined bluebird in 2011 with broad operations, business development, commercial development, program management, strategy and global finance responsibilities. As COO/CFO, helped drive the company's overall growth from a 20 person start-up to a global 1,200+ employee research, development and commercial enterprise over 9 years. Developed and was responsible for bluebird's severe genetic disease franchise and oncology franchise strategies as well as the overall corporate development strategy including the foundational deal with Celgene/BMS which led to the discovery of Ide-cell (Abecma). Led BLUE's initial public offering in 2013 and subsequent equity financings, totaling over $3 billion. - Active member of the Board of Directors of several biotech companies: Tevard Biosciences and Tenaya Therapeutics (TNYA - Audit Chair and Comp Committee).- Former member of the Board of Directors (Executive Committee Member and Treasurer) of ARM (the Alliance for Regenerative Medicine). - Former chief business officer of Taligen Therapeutics leading the financial management, commercial development and business development of the company. Played a key role in the growth of the company as well as the sale of Taligen to Alexion Pharmaceuticals in January 2011.- Previously held senior level business development, finance, strategic planning and operations roles at Allscripts (MDRX), PathoGenesis (PGNS sold to Chiron for $700 million), EXACT Sciences (EXAS) and Inotek Pharmaceuticals.- Started career at SmithKline Beecham in finance, worldwide business development and managed care contracting roles.- Received M.B.A. from the Kellogg Graduate School of Management at Northwestern University and B.A. from Yale University.Specialties: Strategy, Financial Management, M&A, Business Development, Legal, Business Operations, Fund Raising, Commercial Development & Culture Building
-
Chief Executive OfficerNchroma Bio Dec 2024 - Present
-
Executive Teaching FellowQuestrom School Of Business, Boston University Sep 2022 - PresentBoston, Ma, Us -
Board Member, Chair Of The Audit Committee, Compensation CommitteeTenaya Therapeutics Mar 2020 - PresentSouth San Francisco, California, UsTenaya is a company with a mission to discover, develop and deliver curative therapies that target the underlying causes of heart disease. Tenaya was founded by world leading scientists and seeks to address heart disease through three distinct and multi-modality platforms: a Regeneration Platform; a Gene Therapy Platform and a Precision Medicine Platform. -
Board MemberTevard Biosciences Jan 2018 - PresentAmazing new company dedicated to finding a cure for rare genetic diseases with an initial focus on genetic forms of epilepsy including Dravet Syndrome. I am privileged to work with such an amazing team of dedicated parents, passionate leaders and world-renowned scientists.
-
Chief Executive OfficerNvelop Therapeutics Mar 2023 - Dec 2024Cambridge, Massachusetts, UsNvelop Therapeutics was founded in 2022 to address the challenge of efficiently delivering therapeutic cargoes to target cells in vivo. Nvelop’s next-generation platforms enable highly efficient and cell-specific in vivo delivery of a wide range of cargoes to many types of target cells. The two platforms were independently developed in the labs of scientific co-founders and gene editing pioneers Dr. David Liu of the Broad Institute of MIT and Harvard, and Dr. Keith Joung at Massachusetts General Hospital. With its own pipeline of therapeutics and through strategic collaborations, Nvelop aims to use these programmable, non-viral platforms to transform delivery for a broad range of genetic medicines and modalities in order to treat many previously undruggable diseases. Based in Cambridge, Mass., Nvelop is backed by top life science investors including Newpath Partners, Atlas Venture, F-Prime Capital, 5AM Ventures, GV, and ARCH Venture Partners. -
Venture PartnerThird Rock Ventures Jan 2022 - Mar 2023Boston, Ma, Us -
Strategic AdvisorBluebird Bio Jan 2020 - Mar 2021Somerville, Massachusetts, Us -
Chief Financial And Strategy OfficerBluebird Bio May 2011 - Jan 2020Somerville, Massachusetts, UsBluebird bio is a commercial stage biotechnology company leading the way in next generation gene therapy technologies and products for the treatment of severe genetic diseases and oncology. Bluebird's novel and proprietary approach has the potential to radically transform the way rare genetic diseases and cancer are treated and managed.
-
Board Member, Executive Committee Member, TreasurerAlliance For Regenerative Medicine Jan 2015 - Jan 2020Washington, District Of Columbia, Us -
Chief Business OfficerTaligen Therapeutics Nov 2008 - May 2011UsTaligen was acquired by Alexion for up to $478 million including $111 million in upfront cash in 2011. As CBO of Taligen, responsible for financial management, business development, strategy, legal and general business operations for this protein therapeutics and antibody biotechnology firm. -
Chief Business OfficerInotek Pharmaceuticals Mar 2004 - Oct 2008Member of Inotek’s Executive Management Team with responsibility for business development, financial and corporate planning, strategic product development, and legal.
-
Vp Business Development And StrategyExact Sciences 2000 - 2004Madison, Wisconsin, Us -
Sr. Director, Coporate Finance & PlanningPathogenesis 1998 - 2000Acquired by Chiron in 2000 for $700 million.
-
Director/Vp, Managed CareAllscripts 1995 - 1998Chicago, Il, Us -
Sr. Manager, Worldwide Business DevelopmentSmithkline Beecham 1987 - 1995Brentford, Middlesex, Gb
Jeff Walsh Skills
Jeff Walsh Education Details
-
Northwestern University - Kellogg School Of ManagementFinance -
Yale UniversityEconomics
Frequently Asked Questions about Jeff Walsh
What company does Jeff Walsh work for?
Jeff Walsh works for Nchroma Bio
What is Jeff Walsh's role at the current company?
Jeff Walsh's current role is Biotech Executive and Board Member with 30+ years of company building experience..
What is Jeff Walsh's email address?
Jeff Walsh's email address is jw****@****ale.edu
What is Jeff Walsh's direct phone number?
Jeff Walsh's direct phone number is +197820*****
What schools did Jeff Walsh attend?
Jeff Walsh attended Northwestern University - Kellogg School Of Management, Yale University.
What skills is Jeff Walsh known for?
Jeff Walsh has skills like Biotechnology, Strategy, Business Development, Mergers And Acquisitions, Life Sciences, Strategic Planning, Finance, Executive Management, Cross Functional Team Leadership, Drug Development, Lifesciences, Venture Capital.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial